Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

ANIX


Fundamental

Company: Anixa Biosciences Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: -
P/E: -
EPS (ttm): -0.38
Insider Own: 5.43%
Shs Outstand: 32.21M
Perf Week: -1.33%
Market Cap: 95.66M
Forward P/E: -
EPS next Y: -0.32
Insider Trans: 2.64%
Shs Float: 30.46M
Perf Month: -11.61%
Enterprise Value: 79.12M
PEG: -
EPS next Q: -0.09
Inst Own: 17.27%
Short Float: 1.37%
Perf Quarter: 16.47%
Income: -12.13M
P/S: -
EPS this Y: 6.77%
Inst Trans: -4.25%
Short Ratio: 2.95
Perf Half Y: -5.41%
Sales: 0.00M
P/B: 5.95
EPS next Y Percentage: 13.15%
ROA: -58.71%
Short Interest: 0.42M
Perf YTD: 28.02%
Book/sh: 0.50
P/C: 6.13
EPS next 5Y: 14.84%
ROE: -61.14%
52W High: 4.20 -29.29%
Perf Year: -6.90%
Cash/sh: 0.48
P/FCF: -
EPS past 3/5Y: 4.60% 7.73%
ROIC: -74.66%
52W Low: 2.07 43.48%
Perf 3Y: -20.16%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - -
Gross Margin: -
Volatility W: 4.89%
Volatility M: 4.99%
Perf 5Y: 6.07%
Dividend TTM: -
EV/Sales: -
EPS Y/Y TTM: -2.11%
Oper. Margin: -
ATR (14): 0.16
Perf 10Y: -44.48%
Dividend Ex-Date: -
Quick Ratio: 8.89
Sales Y/Y TTM: -100.00%
Profit Margin: -
RSI (14): 42.12
Recom: 1.00
Dividend Gr. 3/5Y: - -
Current Ratio: 8.89
EPS Q/Q: 11.99%
SMA20: -6.15%
Beta: 0.59
Target Price: 8.50
Payout: -
Debt/Eq: 0.01
Sales Q/Q: -
SMA50: -8.25%
Rel Volume: 0.57
Prev Close: 3.05
Employees: 5
LT Debt/Eq: 0.01
Earnings: Jun 06
SMA200: 0.03%
Avg Volume: 140.93K
Price: 2.97
IPO: Oct 07, 1983
Option/Short: Yes / Yes
EPS/Sales Surpr.: 5.36% -
Trades:
Volume: 80,402
Change: -2.62%

Technical:


Latest News:

Broadcom acquisition of VMWare creating a storm of uncertainty, risk: Nutanix CEO somewhat bearish
NTNX VMW CSCO NVDA

Summary: Nutanix CEO Rajiv Ramaswami expressed concerns about Broadcom's acquisition of VMware leading to uncertainty and risk in the industry. Nutanix announced collaboration with Cisco to certify Cisco UCS blade servers and streamline customer migrations. Nutanix also shared plans to work with NVIDIA to help enterprises adopt generative AI more easily.

Full article
2024-05-21T17:25:45Z
Nutanix and Cisco grease migration for VMware customers - Blocks and Files somewhat bullish
NTNX

Summary: Nutanix is expanding its offerings to target the installed base of Cisco UCS servers and VMware vSAN systems, making it easier for customers to migrate their hardware. The company is also enhancing its Secure Snapshot capability and strengthening its disaster recovery support for multi-site DR.

Full article
2024-05-21T14:05:06Z
Some straight talk about Broadcom's moves with VMware - Insider somewhat bearish
VMW NUTANIX

Summary: Broadcom has transitioned VMware's perpetual licenses to subscription licenses, causing significant cost increases for End Users, leading to dissatisfaction. Nutanix emerges as a potential winner with its cost-effective HCI platform offering comparable vSphere and vCenter features at no additional cost. Organizations are urged to migrate to HCI for higher performance and lower costs to counter Broadcom's actions.

Full article
2024-05-14T19:34:54Z
Nutanix Upgraded, Viewed As Share-Taker Versus Broadcom's VMware somewhat bullish
NTNX VMW AVGO

Summary: Nutanix's stock rises on analyst upgrade and expectation of gaining customers from rival VMware.

Full article
2024-05-08T15:49:39Z
Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja somewhat bullish
ANIX

Summary: Anixa Biosciences, Inc. announced a podcast interview with Dr. Amit Kumar discussing 'The Vaccine That Could End Breast Cancer'. The interview highlights Anixa's vaccine technology and its potential for preventing and treating cancer.

Full article
2024-05-06T12:07:51Z